Katja Fiedler

Scientist at Curevac Ag

Katja Fiedler's Professional Contact Details

Email (Verified)

****@curevac.com

Get Email Address

+49 7071 98830

Location

TÃ¼bingen, Baden-WÃ¼rttemberg, Germany

Company

Curevac Ag

Person Seniority

entry

Katja Fiedler's Current Company Details

Curevac Ag

TÃ¼bingen, Baden-WÃ¼rttemberg, Germany • 92 Employees

biotechnology

Founded in 2000 as a spin-off from the University of TÏ‹bingen in Germany, CureVac is a leading company in the field of mRNA technology and was the first company to start clin-ical trials on mRNA-based drugs. The biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. The basic principle of CureVac's proprietary technology is the use of mRNA as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. Since its inception, strongly backed by SAP founder Dietmar Hopp's dievini, CureVac has received approximately $420 million (â‚¬400 million) in equity investments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Lilly, Boehringer Ingelheim, Sanofi Pasteur and the Bill & Melinda Gates Foundation. In 2006, CureVac successfully established the worldwide first GMP facility for the manu-facturing of mRNA. In 2017 CureVac started the establishment and construction of industrial scale production facilities.

Founded Year

2000

Organization Website

curevac.com

Organization Languages

English, German

Organization Revenue

35000

Alexa Ranking

584690

Current Technologies

piwik